TRAPPC11

Across TCGA pan-cancer cohorts, TRAPPC11 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRAPPC11 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TRAPPC11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAPPC11 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

STAD, HNSC, and UCEC are the cancer types where TRAPPC11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
HNSC	DFS	Median	II,III,IV	0.178	0.612	.040	6	view →
UCEC	DFS	Median	All	0.950	0.828	.028	6	view →
LUAD	OS	Median	III,IV	0.235	0.677	.030	3	view →
SKCM	DFS	Median	III,IV	0.813	0.236	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRAPPC11–STAD (OS)

Open the STAD breakdown →